Valye reports for unlimited access

Security Midwest Bancorp, Inc. is a Maryland-incorporated financial institution headquartered in Springfield, Illinois. It operates under a governance structure with a nine-member board of directors possessing diverse expertise in banking, accounting, real estate, and small business sectors. The company is a smaller reporting entity with publicly available SEC filings including an amended 10-K and a recent 10-Q. The latest quarterly filing reports net income and earnings per share figures but lacks detailed liquidity and asset metrics. The company maintains a Code of Ethics for senior officers and an Audit Committee with financial expertise.

Valuence Merger Corp. I is a Cayman Islands exempted blank check company formed in August 2021. Its purpose is to complete a business combination with one or more entities, focusing on targets based in Asia (excluding China, Hong Kong, and Macau) that develop breakthrough life sciences or sustainable technology platforms. The company completed its IPO in March 2022, raising over $226 million, which is held in a trust account. It has not commenced operations and generates income only from interest on trust funds. The company has extended its deadline to complete a business combination multiple times, with the current deadline extended to March 3, 2026, and provisions to extend further up to March 3, 2027. The company’s shares are redeemable upon business combination, and its warrants were transferred to the Nasdaq Capital Market due to compliance issues. Trading was suspended on Nasdaq in March 2025 and moved to OTC Pink due to failure to complete a business combination within 36 months of IPO.

BeyondSpring Inc. develops innovative cancer therapies with a focus on its lead asset, Plinabulin, which is being tested in multiple cancer indications including metastatic NSCLC. The company also operates a targeted protein degradation platform through its subsidiary SEED Therapeutics, which is classified as discontinued operations following a divestiture plan. BeyondSpring retains significant equity and control in SEED while engaging in share sales to third parties. The company recognizes revenue under ASC 606 and reports deferred revenue from upfront payments. It leases office space in New Jersey and China and maintains operations in both locations. Financially, BeyondSpring reported a net loss and negative earnings per share in recent periods, with liquidity ratios indicating current liabilities exceed current assets. The company is actively managing financing options and clinical development progress.

Pioneer Power Solutions, Inc. is focused on the Critical Power business segment following the sale of its PCEP operations. The company designs and manufactures electrical equipment and related products, relying on a range of electrical and engine components sourced from multiple suppliers. It serves a concentrated customer base with significant revenue derived from a few large customers. The company maintains a backlog of orders representing a substantial portion of its annual sales, though cancellations can occur. Operations have been curtailed post-PCEP sale, and the company faces challenges in generating positive income and cash flow. It depends on key personnel and third-party distributors and shippers for product delivery and service. The company is exposed to supply chain disruptions, pricing pressures from large customers, and cybersecurity risks. Financially, the company reported a net loss and maintains liquidity with a strong current ratio as of mid-2026.

Reliability Inc, through its wholly owned subsidiary Maslow Media Group, provides comprehensive workforce management solutions including Employer of Record (EOR) services, staffing solutions across media, IT, creative, marketing, and administrative roles, managed services, and video production services. The company serves a diverse client base across multiple industries domestically and internationally. Maslow’s EOR services manage employment compliance and payroll for contingent workers, while staffing solutions offer flexible workforce options including temporary, contract, direct hire, and managed services. Video production services cover end-to-end project management from pre-production to live broadcasts. The company has a history dating back to 1953, transitioning from semiconductor equipment manufacturing to workforce solutions after 2007. It employs approximately 589 personnel, including full-time and field talent workers. The business operates in a highly fragmented and cyclical staffing industry influenced by economic conditions and regulatory developments.

Franklin Ethereum Trust is a Delaware statutory trust formed in early 2024 that offers a single series, the Franklin Ethereum ETF (ticker EZET). The Fund provides investors with exposure to the price of ether through a passive investment vehicle that holds ether directly, managed by a Sponsor who does not actively trade the underlying asset. Shares represent fractional interests in the Fund's net assets, primarily consisting of ether held by Coinbase Custody. The Fund's NAV is calculated daily based on a regulated benchmark index aggregating ether spot prices from multiple exchanges. Shares trade on the Cboe BZX Exchange, allowing investors to access ether exposure via traditional brokerage accounts without managing wallets or private keys. The Fund charges a 0.19% annual Sponsor fee covering most expenses, with the Fund selling ether as needed to pay fees and other costs. The Fund reported a net loss in the most recent quarter, reflecting operational expenses and market conditions. The Fund is not registered as an investment company and does not have voting rights for shareholders except as granted by the Sponsor.

Nuburu, Inc. is a publicly traded company on the NYSE American exchange under the ticker BURU. The company focuses on advanced blue laser technology, particularly for defense applications, operating through subsidiaries such as Nuburu Defense, LLC and Lyocon S.r.l. Leadership includes Executive Chairman and Co-CEO Alessandro Zamboni and Co-CEO Dario Barisoni, both appointed in 2025. The Board of Directors has expertise in technology, finance, and corporate governance. Nuburu has formal corporate governance and risk oversight processes. Financially, as of Q2 2026, the company reported modest revenue with a net loss and liquidity ratios indicating current liabilities exceed current assets. The company has undertaken strategic financial maneuvers, including equity restructuring and a public offering to support growth and acquisitions. Nuburu is also exploring strategic alternatives including potential sale.

Tevogen Bio Holdings Inc. is a biotechnology company focused on developing immunotherapy treatments and leveraging AI technologies to accelerate clinical trial participation and drug development. The company operates with a board of six directors and key executives including CEO Dr. Ryan Saadi. It has launched the Tevogen.AI platform and is advancing its ExacTcell pipeline. Tevogen Bio is actively pursuing strategic acquisitions to expand its revenue base and has recently signed a letter of intent to evaluate an MSO acquisition. The company is publicly traded on Nasdaq and has undergone a reverse stock split in 2026.

Amaze Holdings, Inc. is a technology-driven commerce platform focused on enabling creators, brands, and consumers to transact at scale. Following its acquisition of Amaze Software, Inc. in March 2025, the company shifted from a consumer-packaged goods business to a software-enabled commerce, data, and distribution platform serving the creator economy. The platform offers integrated tools for storefront creation, product design, payment processing, order management, and fulfillment, operating an asset-light model that leverages third-party manufacturing and logistics partners. Amaze generates first-party transaction data from platform activity, which it is developing to improve targeting, personalization, and monetization. The company is also building verticalized distribution channels, including the Food Channel, to organize creators and content by category and enhance consumer engagement. The legacy wine business remains but is not a strategic focus. Amaze competes with established e-commerce platforms, creator monetization services, print-on-demand providers, and digital advertising platforms, differentiating itself through integrated commerce and data capabilities. The company is subject to various regulatory requirements including data privacy and consumer protection laws.

TSS, Inc. provides a comprehensive suite of services for integrating complex AI technologies and IT infrastructure in mission-critical facilities such as data centers and modular data centers. Its offerings include technology consulting, design and engineering, project management, systems integration, installation, facilities management, and IT procurement services. The company operates a centralized ISO-certified integration facility in Georgetown, Texas, following a relocation and $40 million capital investment to enhance power and cooling capabilities for AI-enabled server racks. TSS’s business is highly concentrated, with a single US-based IT OEM customer accounting for the vast majority of revenues and receivables. The company’s revenue model includes both gross and net procurement deals, reflecting its role as both principal and agent in various transactions. TSS competes in a dynamic and competitive market driven by rapid AI infrastructure adoption and evolving data center technologies.

Franklin Crypto Trust is a Delaware statutory trust offering the Franklin Crypto Index ETF (ticker EZPZ), which seeks to provide investment results closely corresponding to the CF Institutional Digital Asset Index – US–Settlement Price. The Fund invests passively in a basket of digital assets including Bitcoin, Ether, XRP, Solana, Dogecoin, Cardano, Chainlink, and Stellar Lumens, weighted by free float market capitalization. Shares are issued and redeemed in Creation Units of 50,000 shares by authorized participants and trade on the Cboe BZX Exchange. The Fund's NAV is calculated daily based on CF Reference Rates aggregating spot market data from multiple exchanges. Custody of digital assets is provided by Coinbase Custody Trust Company, with Coinbase Inc. as Prime Broker. The Sponsor is Franklin Holdings, LLC, and The Bank of New York Mellon serves as Administrator and Cash Custodian. The Fund is an emerging growth company and may comply with reduced reporting requirements. The Fund's financial statements show net investment losses and net realized and unrealized losses on digital assets for 2025, with net assets increasing due to capital contributions. The Fund's Sponsor assumes ordinary expenses but not extraordinary expenses, which the Fund must cover. Authorized Participants include major financial institutions such as Jane Street Capital and Goldman Sachs. The Sponsor has discretion to terminate the Fund with notice to shareholders.

XBP Global Holdings, Inc. operates as a multinational technology and services company delivering intelligent workflow solutions powered by AI-driven automation. Its offerings enable clients to transform labor-intensive operations into digitally orchestrated, exception-driven workflows. The company serves clients primarily in the Americas, Europe, and Asia, with deep domain expertise in regulated industries such as banking, healthcare, and insurance. XBP Global's business segments include Applied Workflow Automation, which focuses on transaction processing and enterprise information management services, and Technology, which provides software licenses, hardware solutions, and professional services. The company has a global presence with over 10,600 employees across 20 countries and operates a portfolio of leased and owned facilities worldwide. It completed a business combination in 2023 acquiring European operations and expanded in 2025 by acquiring BPA's Americas and Asia operations, consolidating a platform with over 50 years of history. The company is listed on Nasdaq under ticker XBP.

ASP Isotopes Inc. is a publicly traded company focused on helium production and radiopharmacy expansion. The company operates the Renergen Helium Project and has secured its first helium sales contract through its Tetra4 subsidiary. ASP Isotopes is advancing a listing for Noble Africa as its helium project nears production. The company has raised capital through registered direct offerings, including a $60 million underwritten offering in 2025. As of mid-2026, ASP Isotopes holds substantial liquidity with over $219 million in cash and equivalents and maintains a strong current ratio. The company reported modest revenue and a net loss for the quarter ended June 30, 2026. Governance is overseen by a seven-member board with significant independent representation and committees for audit, governance, and compensation. The company faces risks related to a pending merger with ENDRA, including conditions for completion and integration challenges.

Franklin Templeton Holdings Trust is a Delaware statutory trust formed in 2021 that offers a single series ETF, the Franklin Responsibly Sourced Gold ETF (FGDL). The Fund's objective is to reflect the price performance of gold bullion less expenses by holding only gold bullion and cash. It focuses on responsibly sourced gold refined after 2012 according to LBMA standards. Shares represent fractional undivided interests in the Fund's gold bullion and cash and are created and redeemed in Creation Units of 50,000 shares by authorized participants in exchange for gold bullion. The Fund's expenses are limited to a 0.15% annual sponsor fee, with the sponsor covering most ordinary expenses. The Fund is not registered as an investment company and does not have officers or directors. The NAV is calculated daily based on LBMA gold prices. Shares do not confer traditional shareholder rights and are held in book-entry form through DTC. The Sponsor may terminate the Fund at its discretion with notice to shareholders.

Franklin XRP Trust is a Delaware statutory trust formed in 2025 that offers the Franklin XRP ETF, a passive investment vehicle designed to track the price of XRP net of expenses. Shares are listed on NYSE Arca under the ticker XRPZ and represent fractional ownership of the Fund's XRP holdings. The Fund does not actively trade or leverage its XRP assets and relies on Coinbase Custody for digital asset custody and BNY Mellon for administrative services. The Fund's NAV is calculated daily using the CF Benchmarks Index, which aggregates spot XRP prices from multiple exchanges. The Sponsor charges an annual fee of 0.19% of net asset value, covering ordinary expenses, with fee waivers applied on initial assets. The Fund reported a net loss of $67.4 million for the quarter ended June 30, 2026. Shareholders have limited voting rights, and the Sponsor retains the right to terminate the Fund with notice. The Fund's XRP is primarily held in cold storage with a portion in trading balances to facilitate transactions [S1][S2].

Piermont Valley Acquisition Corp is a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands. It was formed to effect a business combination with one or more operating businesses but has not commenced substantive operations or generated operating revenues. The company holds funds in a Trust Account invested primarily in U.S. Treasury Bills and money market funds. Its management and board structure reflect its status as a shell company, with a single director and non-operational board committees until a business combination is completed.

Healthy Choice Wellness Corp. is a holding company operating natural and organic grocery and dietary supplement retail stores through several subsidiaries under well-known local brands. The company emphasizes high-quality, USDA certified organic products, strict quality standards excluding artificial additives and hormones, and a customer service model centered on nutrition education and community engagement. It operates stores in Florida, New York, New Jersey, Virginia, Kansas, and Oklahoma, offering approximately 10,000 SKUs including groceries, produce, bulk foods, vitamins, supplements, health and beauty products, and household items. The company also sells products online through its Healthy U Wholesale subsidiary. HCWC completed a spin-off from Healthier Choices Management Corp. in September 2024 and trades on the NYSE American under ticker HCWC. The company pursues growth through store acquisitions, increasing sales per customer, new revenue streams such as in-house baking commissaries and wholesale supply, and customer base expansion via marketing and website improvements. Pricing strategies include advertised discounts and in-store specials. The company sources from about 1,000 suppliers and competes with a broad range of grocery and supplement retailers. As of June 30, 2026, HCWC reported a net loss and liquidity ratios indicating current liabilities exceed current assets, with ongoing initiatives to improve profitability and liquidity.

Waste Energy Corp. operates in the clean-energy sector, developing a waste conversion platform that thermally processes non-recyclable waste tires and plastics in an oxygen-restricted environment to produce tire-derived oil, recovered carbon black, recovered steel, and synthetic gas. The company is also developing an AI-based platform for emissions monitoring and carbon credit management. Incorporated in 2010, the company shifted focus to waste-to-energy in 2024 and is advancing commercial deployment at its Midland, Texas site. The Midland facility is designed for modular expansion from 15 to 60 tons per day. The company has not yet commenced commercial operations and has limited revenue history. Its business model includes multiple revenue streams from product sales, processing fees, environmental credits, and consulting/licensing. The company faces significant operational, financial, and regulatory risks typical of early-stage clean-energy ventures [S1][S2].

Nuo Therapeutics, Inc. develops and markets the Aurix System, an autologous platelet rich plasma (PRP) medical device cleared by the FDA in 2007 for chronic wound care management. The Aurix System processes a patient's own blood at the point of care to produce a biologically active gel that delivers growth factors and signaling molecules to promote healing of chronic wounds such as diabetic foot ulcers, leg ulcers, and pressure ulcers. The company operates primarily in the U.S. advanced wound care market, estimated at $10.8 billion globally in 2021. After a period of ceased operations in 2019 pending Medicare coverage reconsideration, Nuo Therapeutics resumed commercial activities in 2021 following a favorable CMS National Coverage Determination. The company has established a sales network of over 200 representatives and entered a distribution agreement with Smith+Nephew for a private label Aurix product. Manufacturing is outsourced, with a critical reagent sourced solely from Pfizer. Recent supply interruptions of this reagent have caused temporary product shortages. Financially, the company reported a net loss and maintains a current ratio above 1 as of mid-2026.

Positron Corporation is a medical technology company specializing in the development, manufacture, and sale of PET and PET-CT imaging systems, with a primary focus on cardiac PET imaging. The company aims to improve diagnosis and treatment of cardiovascular disease and other critical conditions by providing high-performance, cost-effective molecular imaging solutions. Positron combines proprietary imaging technology with comprehensive clinical and technical support, flexible financing options, and operational efficiency to facilitate adoption across hospitals, outpatient centers, and physician practices. The company has a strategic partnership with Neusoft Medical Systems for manufacturing and distribution in North America and is preparing to launch its next-generation Affinity PET-CT 4D system to expand clinical applications into oncology and neurology. Positron operates in a competitive market dominated by large multinational OEMs but differentiates through its cardiac PET focus, integrated service model, and cost-effective pricing.

Harte Hanks Inc. operates as a publicly traded company with recent financial disclosures showing quarterly revenue and net loss figures. The company is engaged in a pending acquisition by Star Equity, which introduces operational restrictions and merger-related risks. Recent financial results indicate challenges including revenue declines and pension-related costs. The company faces uncertainties related to the completion and integration of the merger, as well as ongoing transaction expenses.

PodcastOne, Inc. is a digital media company specializing in podcast content and platform services. The company has operated at a net loss since inception, reflecting ongoing investments in content expansion and platform development. It is a subsidiary of LiveOne, which holds significant secured debt that impacts PodcastOne's financial and operational flexibility. The company’s financial position as of mid-2026 shows modest liquidity with cash and current assets slightly exceeding current liabilities. PodcastOne continues to face challenges in achieving profitability and sustaining operations without additional financing or revenue growth.

AMASS BRANDS operates in the organic non-alcoholic wine market, with its Good Twin brand holding a leading position in the U.S. market. The company reported quarterly revenue and net loss figures in its latest SEC 10-Q filing for the period ending June 30, 2026. Liquidity metrics show current liabilities surpass current assets, with a current ratio of 0.7 and a low cash ratio, suggesting potential short-term liquidity challenges. The company is classified as a smaller reporting company and references risk factors disclosed in its recent prospectuses.

Transcode Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA-based therapeutic candidates primarily targeting cancer. The company is advancing its lead candidate, TTX-MC138, through clinical trials, including Phase 1 and planned Phase 2a studies. Transcode has engaged in strategic acquisitions such as Polynoma from CK Life Sciences and has raised capital through private placements to support its development programs. The company operates under Nasdaq listing rules and is classified as a controlled company due to majority ownership by CK Life Sciences. Its Board of Directors comprises experienced biotech and financial professionals.

StableCoinX Inc. is a digital asset infrastructure company developing and expanding multiple complementary business lines. Its Infrastructure Services include validator operations and a decentralized verification network (DVN) platform launched in late 2025. The company also offers the StableCoinX Harness, an enterprise middleware platform launched in mid-2026 to facilitate integration of Ethena's digital dollar products into financial workflows. Additionally, StableCoinX is developing Distribution Services aimed at institutional adoption of Ethena's digital dollar products through product distribution, capital formation, and financing transactions. The company’s business model depends on the growth and adoption of the Ethena ecosystem and involves managing multiple early-stage business lines with associated operational, technical, and regulatory risks.

TruGolf Holdings, Inc. is a company specializing in virtual golf technology, including golf simulators, portable launch monitors, and AI-enhanced coaching products. The company has a leadership team with deep experience in gaming and software development. TruGolf pursues growth through product innovation, franchising, and regional expansion. It has recently acquired an AI firm to enhance its technology offerings and has engaged financial advisory services to support its operations. The company faces challenges related to Nasdaq listing compliance and reports ongoing net losses despite revenue growth.

LiveOne, Inc. is a creator-first music and entertainment platform focused on delivering live and virtual music experiences globally. The company operates four core services: LiveOne (live music streaming), Slacker (streaming music service), PodcastOne (podcasting platform), and Custom Personalization Solutions (personalized merchandise). LiveOne's platform offers access to live events, audio streams, podcasts, vodcasts, video on demand, and social sharing. Revenue streams include paid user subscriptions, advertising, licensing, sponsorships, pay-per-view events, and merchandise sales. The company distributes content via internet streaming, satellite, and OTT platforms accessible on multiple devices including automotive OEM integrations. LiveOne holds numerous patents related to streaming technology and operates a large podcast network. The company has a significant customer concentration with Tesla, which subsidizes some users and licenses the LiveOne app for its vehicles. LiveOne faces competition from major streaming services, broadcast radio, and other entertainment platforms. The company has a history of net losses and substantial indebtedness, with liquidity and going concern considerations disclosed in recent filings.

GSR V Acquisition Corp. is a Cayman Islands exempted blank check company formed in July 2025 to pursue a Business Combination with one or more unidentified entities. The company completed its IPO in May 2026, raising gross proceeds of $230 million plus a private placement of approximately $6.7 million. It holds these proceeds in a trust account and generates non-operating income from interest. As of June 30, 2026, it had not commenced operations and has no revenues, focusing on identifying and completing a Business Combination within an 18 to 21-month window.

LightWave Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. It was formed to complete a business combination with one or more target businesses, primarily focusing on the technology sector but open to other industries and geographies. The company completed its IPO in June 2025, raising approximately $215.6 million, which is held in a trust account invested in low-risk government securities. The company has no operating business and intends to use the IPO proceeds and additional financing options to acquire an established business with growth potential. The management team has prior SPAC experience and capital markets expertise. The company’s units were separated into Class A ordinary shares and warrants trading on Nasdaq under the symbols LWAC and LWACW, respectively. As of June 30, 2026, the company reported net income and maintains a strong liquidity position with a current ratio of 1.84.

Nuvve Holding Corp. develops and operates an AI-driven vehicle-to-grid (V2G) technology platform called GIVe, which aggregates electric vehicle (EV) and stationary batteries into virtual power plants (VPPs) to provide bidirectional energy services to electrical grids globally. The platform enables EV owners and fleet operators to monetize unused battery capacity by participating in grid services such as frequency regulation, demand response, and energy optimization, thereby reducing the total cost of EV ownership. The company focuses on commercial fleet segments, including North American school buses, and operates across Europe, Asia, and North America. Nuvve integrates its technology into V2G-capable charging stations and stationary batteries supplied by partners and generates revenue from hardware sales, recurring grid services, mobility fees, and engineering services. The company has a history of net losses and operates with a capital-light model emphasizing research, development, and sales expansion [S1][S2].

Nexscient, Inc. is a smaller reporting company focused on AI and advanced computing technologies. It has expanded its capabilities through acquisitions such as Flipside AI, which specializes in physical AI data engineering. The company also formed a strategic alliance with Tekcapital to source university-originated technologies aligned with its AI focus. Nexscient operates NXNT Labs to support its AI initiatives and has acquired generative AI software applications. The company reported revenues of approximately $1.1 million and a net loss of about $0.56 million for the quarter ended June 30, 2026, with liquidity ratios indicating current liabilities exceed current assets.

Longevity Health Holdings, Inc. is a Delaware-based company engaged in the development, marketing, and sale of cosmetic skincare and haircare products, including those derived from human tissue. The company launched its initial product line in 2024 and has expanded through acquisitions such as Elevai Exosomes in 2025. It operates in a highly competitive cosmetics industry dominated by large multinational companies with extensive resources and brand recognition. Longevity faces challenges related to market acceptance, product quality, regulatory compliance, and the need to build sales and marketing capabilities. The company has entered merger agreements to expand plasma collection operations and has raised capital through equity offerings. As of mid-2026, Longevity reported liquidity constraints and net losses, reflecting ongoing operational and financial challenges.

HIVE Digital Technologies Ltd. operates as a sustainable-energy focused digital infrastructure company. Its core business is hashrate services, generating Bitcoin mining hashrate sold to mining pools under an FPPS payout model. The company retains mined Bitcoin securely without collateralization or staking. HIVE is expanding into AI and HPC infrastructure through its subsidiary BUZZ HPC, upgrading existing Tier-I data centers to Tier-III enterprise-grade facilities optimized for high-density GPU workloads and liquid cooling. The company operates data centers in energy-advantaged regions including Canada, Sweden, and Paraguay, primarily powered by hydroelectric energy. As of mid-2026, HIVE's installed hashrate is approximately 25.2 EH/s with a fleet efficiency around 16.5 J/TH, utilizing about 393 MW of power capacity. The HPC business operates about 5,000 GPUs across Tier-III data centers, serving AI workloads such as large language model computations. Financially, the company reported quarterly revenue of $79.12 million and a net loss of $142.9 million as of June 30, 2026, with strong liquidity metrics including $208 million in cash and equivalents and a current ratio of 1.96. Capital was raised through exchangeable senior notes in 2026, supporting equipment upgrades and business expansion. Management includes experienced executives with backgrounds in blockchain, investment, and technology sectors [S1][S2].

Equus Total Return, Inc. is a publicly traded company listed on the NYSE under ticker EQS. The company is undergoing a transition to become an operating company and may consolidate with another commercial enterprise. It reported a net loss of $14.164 million for the fiscal year ended December 31, 2025, with negative earnings per share. The company holds cash, cash equivalents, and significant short-term investments. Recent developments include efforts to regain compliance with NYSE listing standards, an increase in net assets and share value in early 2025, and governance changes following the passing of its Chairman.

Keen Vision Acquisition Corp. operates as a special purpose acquisition company (SPAC) with the objective of effecting a business combination with a growth-focused company in the biotechnology, consumer goods, or agriculture sectors. The company was incorporated in the British Virgin Islands in 2021 and completed its initial public offering in July 2023, raising gross proceeds of approximately $149.5 million. The proceeds are held in a trust account to be used for the initial business combination. The management team and sponsors bring over 55 years of combined experience in private equity, corporate operations, and mergers and acquisitions, with a focus on leveraging global networks and expertise to identify and complete a suitable business combination. The company’s acquisition criteria emphasize industry leadership, growth potential, ESG imperatives, and operational resilience. As of mid-2026, the company has entered into a letter of intent with Medera Inc., a company engaged in pre-clinical human disease modeling and drug discovery, for a potential business combination. The company’s financial position as of June 30, 2026, shows limited liquidity and a net loss for the quarter, reflecting ongoing operating costs and investment activities.

OS Therapies Inc is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma, a rare and aggressive bone cancer primarily affecting children and young adults. The company's lead product candidate, OST-HER2, is a genetically engineered Listeria monocytogenes-based immunotherapy targeting the HER2 antigen, designed to prevent metastasis and recurrence of Osteosarcoma. OST-HER2 has received orphan drug and rare pediatric disease designations from the FDA. The company completed a Phase IIb clinical trial with 41 patients, demonstrating statistically significant improvements in event-free survival and overall survival compared to historical controls. OST-HER2 was generally well tolerated with no treatment-related deaths reported. OS Therapies is actively engaging with regulatory agencies including the FDA, MHRA, and EMA, with submissions of Biologics License Applications and Marketing Authorization Applications planned. The company also owns a tunable antibody-drug conjugate platform (OST-tADC) in preclinical development targeting multiple solid tumors. Financial disclosures indicate liquidity challenges and recurring losses, with secured debt financing in place. The company has received multiple buy recommendations from analysts in recent months.